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Abstract 
Lung disease is the major cause of death and hospitalization worldwide. Transcription factors such as transcription 
factor 7 (TCF7) are involved in the pathogenesis of lung diseases. TCF7 is important for T cell development and differ-
entiation, embryonic development, or tumorogenesis. Multiple TCF7 isoforms can be characterized by the full-length 
isoform (FL-TCF7) as a transcription activator, or dominant negative isoform (dn-TCF7) as a transcription repressor. 
TCF7 interacts with multiple proteins or target genes and participates in several signal pathways critical for lung 
diseases. TCF7 is involved in pulmonary infection, allergy or asthma through promoting T cells differentiating to Th2 or 
memory T cells. TCF7 also works in tissue repair and remodeling after acute lung injury. The dual roles of TCF7 in lung 
cancers were discussed and it is associated with the cellular proliferation, invasion or metastasis. Thus, TCF7 plays criti-
cal roles in lung diseases and should be considered as a new therapeutic target.
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Background
Lung diseases are significant causes of death, of which 
chronic obstructive pulmonary disease (COPD), lower 
respiratory infection, or lung cancers are, respectively, 
ranked the number 3, 4, or 5th as the top 10 causes of 
death in 2012 globally, with the number of deaths as 
3.1 million, 3.1 million and 1.6 million respectively [1]. 
In China, lung diseases are the fourth cause of death in 
2012, with death rate at 75.59/100,000 in urban area, and 
103.9/100,000 in rural area, and became the top one rea-
son for hospitalization. The first cause of death in China 
is the malignant neoplasm, among which lung cancer 
is the most common one, causing a total death rate of 
49.73/100,000 in urban area and 38.78/100,000 in rural 
area [2]. There are many types of lung diseases including 
obstructive lung diseases, infectious illnesses, lung can-
cer, respiratory failure, pulmonary edema, pulmonary 
embolism, pulmonary fibrosis and sarcoidosis, as well as 
occupational diseases.
Transcription factors as nuclear proteins bind to spe-
cific DNA sequences and regulate the transcription pro-
cess of the gene, consisting of the largest family of human 
proteins encoded by about 8% of genes in human genome 
[3]. The specific DNA sequences binding to the transcrip-
tion factors become the enhancer or promoter regions of 
the genes regulated. Transcription factors play the role 
in the regulation of the gene transcription through sta-
bilizing or blocking the recruitment of RNA polymerase 
to specific genes, the catalysis of the acetylation or dea-
cetylation of histone proteins, and the recruition of coac-
tivator or corepressor proteins to the transcription factor 
DNA complex [4–6]. Transcription factors are critical 
for a huge number of cellular processes such as growth, 
development, and differentiation by regulating the gene 
expression [7]. Mutations of transcription factors were 
found in human diseases, and were considered as druga-
ble targets for drug discovery and development [8, 9].
Transcription factor 7 (TCF7), also known as T-cell-
specific transcription factor-1 (TCF-1), is a member of 
transcription factors. The recent paper overviewed the 
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biology and functions of transcription factor 7 (TCF7), its 
interactions with other proteins in several critical path-
ways, and potential roles in lung diseases. We will explore 
the important role of TCF7 in pathogenesis, diagnosis, or 
therapies for lung diseases.
Review
Understanding the dual biological functions of TCF7
Structure and location
TCF7 gene was firstly identified as a T lymphocyte-spe-
cific transcription factor in 1991, and belongs to a large 
DNA binding protein family called high-mobility group 
(HMG) box [10, 11]. The TCF7 gene resides on human 
chromosome 5q31.1 and named as TCF7 at the Human 
Gene Mapping 11 workshop [12]. TCF7 gene contains 
multiple exons, of which different splicings transcribe 
to variants of mRNAs. There are two promoters, four 
alternative exons (exon1a, 1b, 4a, and 9), and three splice 
acceptors in the exon 10 of TCF7 gene, while 96 different 
mRNAs could be theoretically translated [13]. At least 
16 different protein isoforms with distinct functional 
properties have been found. mRNAs transcribed from 
the two different promoters can translate to two groups 
of proteins with different functions. The first promoter 
generates mRNA encoding a full-length activating form 
(FL-TCF7) (42–60  kDa), while the second intronic pro-
moter produces a truncated, dominant-negative isoform 
of TCF7 (dnTCF7) (25–40  kDa) [14, 15]. The long iso-
forms contain a C-terminal DNA-binding domain named 
HMG box (encoded by exons 6 and 7), a Groucho bind-
ing domain, as well as an N-terminal β-catenin-binding 
domain (encoded by exon 1a and 1b), while the short iso-
forms lack of the β-catenin-binding domain [13, 16–18] 
(Fig. 1).
TCF7 was initially found to be expressed exclusively 
in T lineage lymphocytes [10], and the level of TCF7 
was high in thymocyte cells and peripheral naive T 
cells, but was undetectable in effector T cells [13, 15, 
19]. After then, TCF7 was also found in other tissues 
in embryonic period, mainly in neuroectodermal cells 
and differentiating mesenchymal cells. The expression 
of TCF7 seemed to be “shut off” around birth in non-
lymphoid tissues [20], while TCF7 was over-expressed in 
malignant tumors, e.g. colorectal cancers [21], prostate 
cancers [22], or breast cancers [23], in addition to lym-
phomas and leukemia derived from T lymphocyte [19, 
24]. However, a number of studies demonstrated that 
TCF7 might act as a tumor suppressor and be dimin-
ished in leukemia [25, 26], lymphomas [27], or colorec-
tal cancers [28]. The dual roles of TCF7 in tumorogenesis 
could be explained by the different functions of variant 
isoforms of TCF7 and the complexity of tumor variations 
with multiple signaling pathways in the process of tumor 
development. The distribution of different TCF7 iso-
forms was found to vary between tumors and normal tis-
sues in colon cancers or mammary tumors [29, 30]. It was 
detected that the dominant TCF7 isoform had short-life 
and existed in both nucleus and plasma in normal cells 
such as proliferating intestinal epithelial cells and basal 
epithelial cells of mammary gland epithelium, while the 
full-length isoform in tumor cells and mainly appeared in 
plasma. The balance between the full- and short-length 
isoforms seems to be a checkpoint for promoting or 
inhibiting tumor genesis and development.
Regulating and regulated roles of TCF7 gene
The expression of TCF7 gene is regulated by a number 
of factors through multiple signaling pathways. TCF7 
is enhanced by β-catenin and TCF7L2 (also known as 
TCF4) as a downstream target gene of Wnt pathway. 
Two TCF-binding motifs were found at 1.2 kb upstream 
of promoter I of TCF7 gene on a CpG island that acts as 
an enhancer. The enhancer can be trans-activated by the 
combination of β-catenin and TCF7L2, while the domi-
nant negative isoform of TCF7L2 could inhibit the tran-
scription. TCF7 represses the target genes of β-catenin 
and TCF7L2, forming a negative feedback loop (Fig.  2). 
The process can be regulated through the counteraction 
of dnTCF7 with TCF7L2 target genes such as c-myc and 
cycline D1 [30]. TCF7 promoters do not contain the A/
Fig. 1 TCF7 gene structure. TCF7 gene contains multiple exons. Different splicing may transcribe to variants of mRNAs, and translates to different 
protein isoforms. Exon Ia, Ib, IVa, and IX are alternative exons. There exits two promoters as shown in the figure. The first promoter can generate 
mRNAs encoding a full-length activating form of protein isoforms which contains the β-catenin binding domain, while the second promoter can-
not and thus produce the truncated dominant-negative isoforms. Therefore, two different groups of TCF7 isoforms function differently.
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TA/TCANA G binding motif that can interact with TCF7 
protein, therefore people used to consider that TCF7 
could not be autoregulated [18]. But recent studies found 
that TCF7 could bind to the TCF7 locus and induce 
TCF7 gene expression [31].
TCF7 may be involved in the T cell differentiation, 
evidenced by the finding that TCF7 expression highly 
expressed in naïve T cells, down-regulated in effector T 
cells, and up-regulated again in memory T cells in the 
process of T cell differentiation [32]. TCF7 was proposed 
to regulate the activation of T cells and the production of 
their cytokines, and be simultaneously regulated by TCR 
stimulation and cytokines such as IL-4, IL-2, IL-15, IL-7 
and IL-12 in human naïve CD8 T cells, especially through 
the dnTCF-1 isoform [15, 17, 33]. T cell cytokines could 
inhibit the inhibitory isoform of TCF7 and then facili-
tate the activation of naïve T cells into effector T cells, 
since TCF7 functions as a promoter factor in T cell 
differentiation.
Dual roles of TCF7 in transcription
TCF7 protein is generally known as a transcription fac-
tor. FL-TCF7 functions as a transcription activator, while 
dnTCF7 acts as a transcription repressor. Both isoforms 
of TCF7 could bind with Groucho co-repressors and act 
as a transcription repressor without β-catenin signaling, 
while FL-TCF7 could interact with β-catenin and induce 
the transcriptional activation when β-catenin accumulat-
ing in the nucleus. The dnTCF7 isoform lacks the N-ter-
minal β-catenin binding domain and was proposed to 
play a negative role in transcription regulation [34]. The 
FL-TCF7 was considered to have dual functions in regu-
lating gene transcription through the interaction with 
different proteins. In addition to Groucho family pro-
teins, the β-catenin/TCF7-mediated transcription pro-
cess could also be interfered directly by a multidomain 
protein, Bcr (breakpoint cluster region), to dissociate 
β-catenin/TCF7 complex and down-regulate the level 
of β-catenin/TCF7 target genes such c-Myc [35, 36], as 
shown in Fig. 3. Exogenous aptamers can also affect the 
formation of β-catenin/TCF7 complex, for example, RNA 
aptamer could specifically bind to TCF7 and inhibit its 
binding to β-catenin [37].
Role of TCF7 in the development of T cells and ILC2
TCF7 is an important factor for the development and 
differentiation of T-lineage cells, both in the thymus and 
the peripheral. Progenitor T cells in thymus undergo 
several stages and differentiated into naïve T cells and 
migrate to the peripheral. The peripheral naïve T cells 
then undergos another differentiation upon antigen 
encounter, and become effector T cells [38]. TCF7 is 
found highly up regulated in early thymic progenitors 
(ETPs), promotes the expression of T-lineage genes, 
and is critical for T cell specification. Although TCF7 
Fig. 2 Negative feedback loop between β-catenin/TCF7L2 and TCF7. 
The Wnt signaling leads to the accumulation of β-catenin in the 
nucleus, which bind to TCF/LEF family of transcription factors. TCF7L2 
is one of the TCF/LEF family members, which activates transcription 
of target genes together with the coactivator β-catenin. Although as 
a TCF/LEF member, TCF7 is also a target gene of β-catenin/TCF7L2. 
The dominant negative isoform of TCF7 protein negatively feedback 
to β-catenin/TCF7L2, functions as a transcription repressor, and 
down-regulates β-catenin/TCF7L2target genes. β-cat β-catenin, 
TCF7L2 transcription factor 7-like 2, dnTCF7 dominant negative tran-
scription factor 7.
Fig. 3 Bcr inhibits TCF7 mediated transcription. Bcr inhibits TCF7 
mediated transcription through binding with both β-catenin and 
TCF7 protein, interferes the formation of β-catenin/TCF7 transcription 
complex, and therefore represses the target gene transcription. β-cat 
β-catenin, TCF7 transcription factor 7, Bcr breakpoint cluster region.
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usually promotes gene transcription with the co-acti-
vator β-catenin, evidence showed that the function 
of TCF7 in early T cell development is not relied on 
Wnt/β-catenin pathway [39, 40], but is closely associ-
ated with the activation of Notch signaling [31]. Even 
so, Wnt/β-catenin/TCF7 pathway is still involved in 
multiple stages of T cell development, supports prolif-
eration of DN thymocytes, promotes DN to DP transi-
tion, enhances DP thymocyte survival and participates 
in positive/negative selection [38]. As in the peripheral, 
TCF7 was considered as a contributor for Th2 but sup-
pressor for Th1 or Th17 cell fate in CD4+ T cells [17, 
41–43], and also promotes the formation of memory 
cells in CD8+ T cells [44] (Fig. 4).
Group 2 innate lymphoid cells (ILC2) are a kind of 
innate lymphocytes that functionally produce Th2 cell 
associated cytokines and mediate innate type 2 immu-
nity [45, 46]. A recent study demonstrated that TCF7 is 
required for the development of ILC2 cells, through both 




CD3E gene encodes CD3-ε polypeptide, which forms the 
T-cell receptor-CD3 complex together with CD3-γ, -δ 
and -ζ, and the T-cell receptor α/β and γ/δ heterodimers. 
TCF7 recognizes the motif sequenced as AACAAAG 
in the enhancer of CD3E gene, and induces the T-cell-
specific expression of CD3-ε polypeptide. TCF7 was 
also found to be able to interact with TCR-α, TCR-β and 
TCR-δ enhancers. TCF7 could promote the formation 
of the TCR/CD3 complex, and act as a key factor in T 
cell development [10]. The low expression of CD3-ε was 
noted in both CD4+ T and CD8+ T cells from periph-
eral blood and pleural effusion of lung adenocarcinoma 
patients. Previous studies showed that NSCLC cells 
could induce the down-regulation of CD3-ε in Jurkat 
T cells which might be responsible for T-cell anergy in 
lung cancer [48]. It is possible that the down-regulation 
of CD3-ε in patients with lung cancer may be related to 
TCF7 dysfunction through the regulation of TCF7 in 
CD3E expression.
Fig. 4 Role of TCF7 in T cell differentiation in thymus and peripheral. In thymus, early thymic progenitor (ETP) cells undergo several stages to form 
mature T cells. The process can be generally divided into three stages: double negative (DN), double positive (DP), and single positive (SP). TCF7 is 
involved in many critical events in the process, and is essential for DN cell proliferation, DN to DP transition, DP cell survival, the positive selection 
and negative selection. TCF7 is also important for peripheral T cell differentiation. TCF7 promotes CD4+ T cells differentiates to Th2 cells and sup-
press Th1 or Th17 cells at the same time. Besides, TCF7 also facilitates the formation of memory CD8+ T cells. TCF7 transcription factor 7, ETP early 
thymic progenitor, DN double negative, DP double positive, SP single positive, Treg regulatory T cell.
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Interactions with β‑catenin
β-catenin, encoded by the CTNNB1 gene on human 
chromosome 3p21, is a key protein in canonical Wnt 
pathway [49], as shown in Fig.  5. Activation of Wnt 
signaling results in the accumulation and/or translo-
cation of the downstream β-catenin in cytosol and/or 
nucleus, to form an active transcription complex with 
TCF/LEF family members including TCF7, TCF7L1, 
TCF7L2 and LEF1 [50]. β-catenin binds to TCF7 at 
the N-terminal β-catenin binding domain, which 
only exists in the full-length isoform of TCF7. The 
β-catenin/TCF7 signaling was reported as an important 
pathway in regulating T cell development, differentia-
tion, or survival [38, 51]. TCF7 gene can encode a pro-
tein to form the transcription complex with β-catenin 
and act as a target gene of Wnt/β-catenin signal-
ing, which could be enhanced by β-catenin/TCF7L2, 
together with Myc, Cyclin D1, PPAR-δ, MMP-7, Axin-
2, or CD44, etc. [30, 50]. There might be a negative 
feedback loop whenTCF7 repressed β-catenin target 
genes [30].
Interactions with TCF7L2
TCF7L2, also known as TCF4, is another member of TCF 
family. There still remains a significant variation between 
TCF7L2 and TCF7, although both proteins function 
as transcription factors that bind to the coactivator 
β-catenin to up-regulate the transcription of target genes. 
The two proteins can interact with each other and form a 
regulation loop, as shown in Fig. 2. TCF7L2 binds to and 
transactivate the enhancer of TCF7 gene with the coacti-
vator β-catenin and promotes TCF7 transcription, while 
TCF7 down-regulates TCF7L2 target genes and acts as 
a feedback repressor of β-catenin/TCF7L2 with a poten-
tial function of tumor suppressor [30]. High expression 
or mutations of TCF7L2 were found in several human 
tumors such as colorectal cancer [52], breast cancer [53], 
liver carcinoma [54], or lung cancer [55]. TCF7L2 was 
suggested to play an important role in the pathogenesis 
of NSCLC. However, a recent meta-analysis came to a 
contradictory conclusion that there is no association 
between TCF7L2 polymorphism with lung cancer [56]. 
The potential tumor-genesis role of TCF7L2 suggested 
Fig. 5 The canonical Wnt pathway. a Wnt is naturally inhibited by inhibitors such as SFRP and WIF. Without a Wnt signal, the β-catenin is captured 
by APC and Axin, then CK1 and GSK3 phosphorilate β-catenin, leading to proteasomal degradation. Without β-catenin binding, the TCF/LEF family 
proteins bind with Groucho family proteins, and function as a transcription inhibitor. b When Wnt signaling activated, Wnt binds to specific Frizzled-
LRP complexes on the cell surface and initiate the canonical Wnt pathway. The activated receptor complex phosphorylates Dvl. Then Dvl inhibits 
CK1 and GSK-3, resulting in the accumulation of non-phosphorylated β-catenin in cytoplasm, which cannot be ubiquitinylated for degradation. 
β-catenin then translocates into the nucleus, and binds with TCF/LEF, causes transcriptional activation of target genes. β-cat β-catenin, LRP low-
density lipoprotein receptor-related protein, CK1 casein kinase 1α, GSK-3 glycogen synthase kinase-3β, Dvl disheveled, APC adenomatous polyposis 
coli, SFRP secreted Frizzledrelated protein, WIF Wnt inhibitory factor, TCF T cell factor, LEF lymphoid enhancer-binding factor.
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a novel method in tumor therapies, which is to inhibit 
TCF7L2 expression or to down-regulate its target genes’ 
expression. Since TCF7 could suppress TCF7L2, it might 
be a promising anti-tumor strategy to introduce TCF7 to 
tumor cells as a treatment.
Interactions with LEF‑1
Lymphoid enhancer-binding factor 1 (LEF-1), also named 
TCF-1a, is another TCF family member and contains a 
DNA-binding HMG box acting as a transcription fac-
tor, similar to TCF7. LEF-1 expresses in T cells and 
pre-B cells to promote thymocyte maturation as a col-
laborator of TCF7 [57, 58]. As downstream factors in 
wnt/β-catenin signaling, both TCF7 and LEF1 levels 
were up-regulated in some tumors such as colon cancers 
[59]. However, more recent studies found a restriction of 
LEF-1 in early thymocytes by the interaction with TCF7, 
so the malignant transformation of developing thymo-
cytes could be prevented as a therapeutic target. LEF-1 
is repressed directly by TCF7 through binding at TCF1 
binding cluster (TBC), a cluster of three motifs located 
around −4.4 kb in the Lef1 locus [25].
Interactions with IL‑17
IL-17, which is an important cytokine involved in infec-
tion, autoimmune response and allergy, is mainly pro-
duced by Th17 cells to promote the formation of Th17 
cells [60]. A special link between IL-17 and asthma has 
been concerned, especially IL-17A and IL-17F of the 
IL-17 family, which were shown to play a pro-inflamma-
tory role in asthma and have the potential association 
with the disease severity [61]. IL-17A was also sug-
gested to be correlated with other airway diseases such 
as COPD [62]. It was found that TCF7 could repress the 
expression of IL-17 gene through the direct binding with 
the promoter region and the second intron of the IL-17 
gene locus. Such repression was proposed to have no 
association with the other factors involved in Th17 dif-
ferentiation, such as RORγt, Stat3, RORα, Ahr, Runx-1, 
Ets-1, Socs3, IRF4, or Batf. There was no connection with 
β-catenin either, although it acts as the co-activator of 
TCF-1 in many other cases [42]. Thus TCF7 could be a 
potential therapeutic target for asthma, COPD and other 
lung diseases associated with high-expression of IL-17 
through inhibiting IL-17 expression.
Interactions with IL‑4
IL-4 is a main Th2 cytokine to promote the differentia-
tion of naïve T cells to Th2 cells, produced by Th2 cells, 
subsequently [63]. IL-4 can stimulate B cell function [64] 
and is associated with chemotaxis of monocytes, mac-
rophages and eosinophils [65, 66]. Paradoxically, anti-
inflammatory functions of IL-4 was also found since it 
down-regulates TNF-α, IL-1, IL-6, IL-12, PGE2, or IL-8, 
which are proinflammatory mediators [67]. IL-4 dis-
plays the dual role in the course of lung fibrosis, plays 
an anti-inflammatory role in initial stages of lung injury, 
and promotes collagen deposition during the later stages 
[68]. TCF7 can promote Th2 cell differentiation through 
transcriptional activation of GATA-3, mainly from the 
proximal GATA-3 promoter at the upstream of exon 1b. 
IL-4 produced by Th2 cells down-regulates the expres-
sion of TCF7 gene and functions as a suppressor of TCF7 
in naïve human CD4+ T cells, mainly through stimula-
tion of STAT6 that interacts with specific DNA motifs of 
human TCF7 locus [17, 69]. IL-4 mainly down regulates 
the short isoform of TCF7, which functions as a tran-
scription repressor and inhibit TCF7-mediated Th2 dif-
ferentiation, thus contributes Th2 differentiation (Fig. 6) 
[17].
Interactions with Eomes
Eomesodermin (Eomes) is a transcriptional factor 
involved in CD8+ T cell memory [70]. TCF7 directly and 
specifically binds to 6 conserved consensus sequences in 
the Eomes 5′-regulatory region, to induce its expression 
and promote the formation and maintenance of memory 
CD8+ T cells [44]. Memory CD8+ T cells in airways 
are involved in the immediate immune response to sec-
ondary virus challenge, and provide a protection from 
secondary infection [71]. Introducing TCF7 to the lung 
would probably be a therapeutic way to protect patients 
from secondary infections through enhancing eomes.
Involvements of signal pathways
Wnt signal pathway
The canonical Wnt pathway regulates a variety of cel-
lular processes, including proliferation, differentiation, 
Fig. 6 Interaction of TCF7 and IL-4. TCF7 promotes Th2 cell differen-
tiation through transcriptional activation of GATA3. Th2 cells produce 
IL-4, which stimulates STAT6 and inhibits dominant negative TCF7, 
which represses the transcription of TCF7 target genes. Therefore, 
through inhibition of dn-TCF7, the process of Th2 cell differentiation 
is promoted. TCF7 transcription factor 7, dnTCF7 dominant negative 
transcription factor 7, GATA3 GATA binding protein 3, IL-4 interleukin 4, 
STAT6 signal transducer and activator of transcription 6.
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survival, apoptosis and cell motility, and plays an impor-
tant role in lung morphogenesis, repair after injury, or 
carcinogenesis (Fig. 5) [72]. When Wnt pathway is acti-
vated, secreted signaling proteins of the Wnt family bind 
to specific Fzd-LRP (Frizzled-low-density lipoprotein 
receptor-related protein) receptor complexes on the cell 
surface and initiate the canonical Wnt pathway, leading 
to the intracellular accumulation of β-catenin [50]. The 
activated receptor complex phosphorylates cytoplas-
mic disheveled (Dvl) which then inhibits casein kinase 
1α (CK1) and glycogen synthase kinase-3β (GSK-3). 
The activation of Dvl-CK1-GSK3 causes the failure of 
β-catenin degradation through ubiquitination and accu-
mulation of non-phosphorylated β-catenin in cytoplasm. 
The stable β-catenin is then translocated into the nucleus 
to form an active transcription complex with TCF/LEF 
family members, resulting in activation of multiple target 
genes, such as c-myc, cyclin D1, matrix metalloprotein-
ases (MMP2, MMP3, MMP7, and MMP9), Cox-2, c-jun, 
Fra-1, VEGFR, or TCF7 [73–82]. In the absence of Wnt 
ligand, TCF/LEF could repress the transcription of target 
genes through the interaction with Groucho family pro-
tein, and function as transcription repressors [34]. TCF7 
also functions as a target gene of Wnt pathway. TCF7L2/
β-catenin could activate the transcription of TCF7, while 
the dominant negative isoform of TCF7 repressed target 
genes of TCF7L2/β-catenin [30]. Therefore, different iso-
forms of TCF7 play totally different roles in the activation 
of Wnt signaling pathway.
The abnormality of Wnt signaling was proposed to be 
associated with the pathogenesis and development of 
lung diseases, e.g. cancer, fibrosis, or pulmonary arterial 
hypertension [79]. Activated Wnt signaling was found 
in NSCLC, with overexpression of Wnt proteins or Dvl, 
the lack of Wnt pathway repressors, e.g. WIF, sFRP1 and 
DKK3, or methylation of the promoter of APC, which 
binds and inhibits β-catenin [83–87]. Target genes such 
as LEF1 and HOXB9 were found to be related with the 
metastasis of lung adenocarcinoma [88]. The Wnt signal-
ing might be also involved in the initial phase or in the 
ongoing multistep process of lung cancerogenesis [79]. 
However, the high level of β-catenin was found cor-
related with better prognosis in patients with NSCLC, 
which seems totally different from colon carcinomas 
or hepatomas [89–91]. The contradictory findings may 
be explained by the multi-function of β-catenin, which 
transduces canonical Wnt pathway and regulates cel-
lular adhesion through the interaction with E-cadherin 
[91]. Overexpression of Wnt genes (WNT2 and −5a), 
the receptors (FZD7 and −10), WNT regulators (sFRP1 
and −2), and Wnt target genes (MMP7) was reported in 
lung fibrosis [92–96], while the expression of TCF7 did 
not increase [97]. Wnt/β-catenin signaling was suggested 
involved in the repair process after lung injury, character-
ized by a decrease of inflammation, re-epithelialization, 
and matrix remodeling. Increased nuclear β-catenin was 
found during the fibroproliferative phase after acute lung 
injury. In addition to the Wnt/β-catenin signaling, the 
β-catenin/E-cadherin pathway was related with the repair 
process [98]. However, there were a number of contra-
dictory reports that β-catenin was not necessary in the 
process of bronchiolar epithelium repair [99]. The para-
doxical results may indicate the complexity of the disease 
pathology and the multiple roles of the Wnt pathway in 
lung diseases.
Activation in FoxO1 signal pathway
FOXO1 belongs to the forkhead family of transcription 
factors and contains a conserved forkhead domain which 
binds to specific DNA sequence and is involved in a 
number of cellular processes, including cell proliferation, 
apoptosis, differentiation, DNA damage or repair, and 
stress responses [100–102]. FOXO1 up-regulates p27 and 
p21 to down-regulate the cell cycle regulator cyclin D1, 
which results in the cell cycle arrest, and plays a poten-
tial role in tumor suppression [103]. FOXO1 expression 
was associated with an earlier stage of lung cancer, the 
less nodal involvement or venous invasion, or a favora-
ble prognosis in NSCLC where apoptosis was induced by 
FOXO1 [104, 105].
FOXO1 plays an important role in the process of 
memory T cell differentiation. It activates the expres-
sion of TCF7, IL7r or Ccr7, through the direct interac-
tion between the highly conserved forkhead-binding 
motif and the promoter region of the target genes [106]. 
FOXO1 could bind to multiple sites close to or within 
TCF7 gene of regulatory T cells and naive CD4+ T 
cells [107]. The activation of Akt phosphorylation could 
directly inactivate FOXO1 and down-regulate TCF7 
expression [108].
The importance of Notch signal pathway
Notch pathway regulates critical cell fate decisions dur-
ing both development and adult life [109], including the 
course of T cell development and differentiation, e.g. the 
decision of CD4+ T cells between the Th1 vs the Th2 
fate [110]. TCF7 is one of the target genes of Notch to 
be up-regulated during the early development of T cells 
[31, 111]. Notch could directly activate TCF7 through 
the interaction with an enhancer 31.5  kb upstream of 
the TCF7 promoter, up-regulating the T-cell essential 
genes, including components of the TCR, or transcrip-
tion factors Gata3 and Bcl11b [31]. Although TCF7 is 
the downstream of Notch, the consistent expression of 
TCF7, GATA3, or Bcl11b was independent on Notch, 
since TCF7 could positively auto-regulate and maintain 
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the expression after the activation [31, 112]. It is prob-
able that secondary factors other than Notch signal-
ing were associated with the up-regulation of TCF7 and 
GATA3 expression during T cell differentiation stages 
of the DN-DP transition [112, 113]. GATA3 expression 
promotes the differentiation of T cells to Th2 cells or 
innate lymphoid cells (ILCs). It was reported that TCF7 
with its coactivator β-catenin negatively regulated Notch 
pathway in thymocytes at CD4-CD8-double-negatve 3 
(DN3) stage or beyond. The expression and signaling of 
pre-TCRα as Notch targets was repressed by TCF7 [114], 
although the mechanism by which TCF7 mediated the 
repression of Notch remains unclear.
The significance of P21 signal pathway
P21 is an important cyclin-dependent kinase (cdk) inhib-
itor and represses the G1-to-S phase transition mainly 
by inhibiting the activity of the cyclin E–cdk2 com-
plex. P21 is related to tumor differentiation and acts as 
a significant factor predicting the prognosis of patients 
with NSCLC [115, 116]. The growth arrest mediated 
by p21 was clarified to be dependent upon the activity 
of C-clamp, a DNA-binding domain other than HMG-
box in the E-tail isoform of TCF1. HMG-box binds Wnt 
response elements (WREs), while the C-clamp contacts 
with 5′-RCCG-3′elements (where R is G or A) upstream 
or downstream of WREs. The C-clamp-RCCG inter-
action could induce the activation of p21 through the 
down-regulation of multiple p21 suppressor genes like 
RUNX1, SMARCA4, SP5, TGIF, or YAP1 at the tran-
scription level, MSI2 at the RNA stability, or CUL4A 
at the protein stability. The up-regulation of p21 by 
dnTCF1E may subsequently cause a stall in the G1 phase 
of the cell cycle [117]. Other studies found that the p21 
promoter could be inhibited by constitutively active TCF, 
and enhanced by dominant negative TCF. N-cadherin 
suppressed β-catenin/TCF, induced p21 expression, and 
lead to a decreased activity of cyclinB-Cdc2 kinase and 
G2/M arrest [118] (Fig. 7).
Potential roles in the pathogenesis of lung diseases
Pulmonary infection
TCF7 is involved in the development or differentiation of 
T cells in the thymus or peripheral circulation, promotes 
the naïve CD4+ T cells into Th2 cells and accelerates the 
formation of memory T cells, which may provide the pro-
tective roles in pulmonary infection [38]. TCF7 was also 
associated with development or differentiation of natu-
ral killer cells or ILC2 cells [47]. There is a need of the 
direct evidence to show the involvement of TCF7 in the 
development of pulmonary infection, even though TCF7 
may have the close relationship with key lymphocytes in 
immune responses against infection.
Pulmonary inflammation
TCF7 was found differentially expressed upon airway 
inflammation. Gene microarray showed TCF7 signifi-
cantly down-regulated in CD4+ T cells from the inflamed 
lung of SPC-HA/TCR-HA mice compared with the lung 
of healthy TCR-HA donors, while no expression differ-
ence was detected in CD4+ T cells from the spleen of the 
same mice [119]. It seemed to be a potential relationship 
between TCF7 and airway inflammation, however, the 
research did not clarify the different isoforms of TCF7, 
and did not show the expression difference between the 
FL-TCF7 that promotes Th2 response and dn-TCF7 that 
repressed by Th2-polarized lymphocytes. Both Th2 and 
ILC2 cells are lymphocytes associated with type 2 immu-
nity, which is characterized by high antibody titers and 
is responsible for the development of asthma and other 
allergic inflammatory diseases through releasing Th2-
type cytokines. Th2-polarized cells down-regulates the 
expression of dn-TCF7. Therefore, dn-TCF7 could prob-
ably be selected as a biomarker for airway inflammation 
[120]. Since FL-TCF7 promotes type 2 immunity, it could 
be a candidate gene target for anti-inflammatory therapy.
Fig. 7 TCF7 in p21 pathway. Different isoforms of TCF7 plays totally 
different role in p21 pathway. The active TCF, includes the full-length 
TCF7 isoform, down-regulates p21, which may inhibits the cyclinB/
cdc2 induced G2 to M phase transition. The β-catenin/TCF medi-
ated cell cycle stall at G2 phase can be repressed by N-cadherin. 
Conversely, the negative isoform of TCF7, one of which is known as 
dnTCF1E, inhibits the p21 repressor genes, thus induces p21 expres-
sion, and arrests the cell cycle at G1 phase through inhibition of 
cyclinE/cdk2 complex. TCF T cell factor, dnTCF1E dominant negative 
E-tail isoform of TCF1.
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Allergy and asthma
TCF7 resides on human chromosome 5q31.1, where was 
proposed as a candidate loci associated with asthma and 
allergy through genome-wide screens [121]. Both Th2 
cells and ILC2 cells promoted by TCF7 were found to 
be involved in asthma. An experimental model of aller-
gic asthma induced by ovalbumin in mice showed TCF7 
was required in the production of the Th2 cytokine, IL-4. 
The TCF7-deficient mice produce less IL-4 and showed 
less inflammation around airways, while the normal mice 
showed more inflammatory cell infiltration in perivas-
cular and peribronchial areas after the challenge with 
ovalbumin. A diminished GATA3-1b expression was also 
detected in TCF7-deficient mice, suggesting that TCF7 
induce IL-4 through GATA-3 pathway and contrib-
ute the development of airway inflammation [41]. ILC2 
induced by TCF7 also contributes to Th2 response, and is 
closely related to asthma. A recent study found that dur-
ing experimental asthma, ILC2 proliferate and produce 
IL-13, which contributes to allergy and worsen the condi-
tion of asthma [122]. The deficiency of TCF7 will lead to 
the lack of ILC2, and contribute relieving type 2 inflam-
mations. Therefore, inhibition of TCF7 in the airway may 
play a protective role in allergic asthma, and might be 
considered as a promising target for the future treatment 
of asthma.
Acute lung injury
TCF7 expression was up-regulated in mice models 
of acute lung injury, accompanied by the increased 
β-catenin protein levels in nuclear localization [98]. 
β-catenin was suggested to play an important role in 
the repair phase after lung injury. The fibroproliferative 
repair was initiated and regulated by the non-canonical 
E-cadherin-β-catenin axis after lung injury induced by 
butylated hydroxytoluene/hyperoxia, through the regu-
lation of the epithelial proliferation and lung matrix 
remodeling. The cytoplasma levels of E-cadherin 
decreased and the nuclear levels of β-catenin increased 
with an increasing expression of the cotranscriptional 
regulators, e.g. TCF7, TCF7L1, or target genes includ-
ing cyclin D1 6  days after the induction of acute lung 
injury [98]. The expression of β-catenin increased in 
type II alveolar epithelial cells in animals with acute lung 
injury [123], probably different from the mechanism by 
which β-catenin was found to be involved in the repair 
and remodeling processes in patients with idiopathic 
pulmonary fibrosis [124]. In addition to the involvement 
of E-cadherin, the Wnt pathway was proposed as one of 
the signaling pathways involved in the repair phase after 
lung injury, evidenced by the finding that Wnt regulated 
lung morphogenesis and development [125]. However, it 
was found that the β-catenin was not necessary for the 
maintenance or efficient repair of the bronchiolar epithe-
lium, since the knockout of β-catenin failed to affect the 
repair of the naphthalene-injured airway [99]. It indicates 
that other pathways may be involved in the repair process 
after lung injury, which should be furthermore clarified 
in future studies.
COPD/emphysema
COPD is the third leading cause of death worldwide, 
characterized by irreversible airflow obstruction and 
loss of functional pulmonary tissue [1]. Emphysema 
is the main feature of COPD with alveolar airspace 
enlargement, parenchymal tissue destruction, and 
impaired pulmonary regeneration [126]. Wnt/β-catenin 
signaling was found to be related with lung develop-
ment and repair after lung injury and was proposed as 
a pathway associated with emphysema. The activity of 
the Wnt/β-catenin signaling pathway and the expres-
sion of its target genes, such as genes of TCF/LEF fam-
ily, were observed decreased in lung tissues of patients 
with COPD or in experimental emphysema, where TCF7 
even was not expressed [127, 128]. Increased activation 
of Wnt/β-catenin showed therapeutic effects in experi-
mental emphysema by increasing pulmonary repair and 
decreasing airspace enlargement, attenuated the com-
promise of parenchymal tissues and restored the struc-
ture and function of alveolar epithelial cells [127]. These 
studies indicated that the up-regulation of the Wnt 
signaling pathway might be a therapeutic strategy for 
emphysema.
Lung cancer
TCF/β-catenin-mediated transcription is an important 
regulator for carcinogenesis of diverse cells [37]. Among 
target genes of TCF/LEF family, cyclin D1 and c-myc are 
responsible for the decision between proliferation and 
apoptosis in the cells, and matrix metalloproteinase-7 
(MMP-7) is related with tumor metastasis [80, 129]. 
Wnt/TCF pathway activation was clarified closely asso-
ciated with the tumorogenesis, development and metas-
tasis of lung cancer, and the metastatic capacity of lung 
adenocarcinoma cells could be suppressed by treatment 
with dominant negative mutants of TCF7 and TCF7L2, 
which suggested that the negative isoforms of TCF7 and 
TCF7L2 might be potential therapies for lung cancer 
[88].
Conclusions
TCF7 is one of important transcription factors for T cell 
development and differentiation, embryonic develop-
ment, or tumorogenesis. Multiple TCF7 isoforms can 
be broadly divided into two groups: the full-length iso-
forms (FL-TCF7) as transcription activators, or dominant 
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negative isoforms (dn-TCF7) as transcription repressors. 
TCF7 interacts with multiple proteins and target genes 
(e.g. CD3E, β-catenin, TCF7L2, LEF-1, IL-17, IL-4, or 
Eomes) and is involved in several signal pathways (e.g. 
Wnt, FoxO1, Notch, or P21pathways) which are criti-
cal for lung diseases, especially the canonical Wnt/β-
catenin pathway. TCF7 is suggested to be involved in 
immune responses to pathogens, autoimmune diseases, 
pulmonary infection, allergy, or asthma through promot-
ing Th2 response, or the formation of memory CD8+ T 
cells. TCF7 also plays an important role in tissue repair 
and remodeling after acute lung injury or in the develop-
ment of pulmonary fibrosis. The dual roles of TCF7 in 
lung cancers were discussed. FL-TCF7 is associated with 
the proliferation, invasion, or metastasis of lung cancer 
cells and the poor prognosis of patients with lung cancers, 
while dn-TCF7 shows therapeutic effect for cancer metas-
tasis. Thus, TCF7 and TCF7-associated regulations play 
critical roles in the pathogenesis and development of lung 
diseases and should be considered as a new therapeutic 
target.
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